In daily life, many patients with coronary heart disease often ask doctors, “their blood lipids are within the normal reference value of the test results, why do they still need to take lipid regulating drugs?” Today, we will talk about this issue. Current medical research suggests that once diagnosed with coronary heart disease, from the risk stratification of “very high-risk patients” (mortality rate of the next 10 years > 10%), should be carried out to strengthen the lipid-regulating treatment, not just because the blood lipid results in the reference range to exclude the use of lipid-regulating drugs, the correct approach for the first choice of statins to regulate the lipid, and “the sooner the better”. The correct approach is to prefer statins, and “the earlier the better”. The goals of control are: LDL cholesterol <1.8 mmol/L and/or LDL-C reduction >50% (i.e., the classic 5018 principle). Because LDL cholesterol in the blood is the “main culprit” in the formation of atherosclerosis, the early acceptance of statins and the achievement of the standard control of blood lipids will help to delay the formation of plaques and stabilize the plaques that have already been formed, thus avoiding the occurrence of angina pectoris, acute myocardial infarction, unstable angina, and so on. The very high-risk patients identified in the multinational guidelines mainly include the following four groups of people: 1, cardiovascular disease: old infarction, acute coronary syndrome, coronary artery revascularization (stenting or coronary artery bypass grafting), other arterial revascularization surgery, ischemic stroke, peripheral arterial diseases. 2, Type 2 diabetes mellitus, type 1 diabetes mellitus combined with target organ damage (e.g. microalbuminuria) 3, Moderate-to-severe chronic kidney disease (GFR <60mL/min/1.73m2) 4, SCORE score >10%. In short, it is recommended that under the guidance of cardiologists in regular hospitals, according to the specific conditions of patients, to decide whether to accept lipid-regulating drug therapy, and if accepting statin therapy, to choose what kind of statin drugs, as well as the dosage and duration of treatment, and so on.